Cade Hildreth, Founder: As the 1ST and ONLY market research firm to specialize in the #stemcell industry, BioInformant has been cited by WSJ, Xconomy, & Vogue.
Joined July 2014
- Tweets 15,682
- Following 9,474
- Followers 18,886
- Likes 6,277
1,872 Photos and videos
Resiliélle® Announces Partnership with Synergy Aesthetics for Exclusive Midwest Representation of Certified Age Zero™ Exosomes - bioinformant.com/resilielle-…
68
Top Companies Developing Cell Therapy Treatments For Diabetes in 2026 - bioinformant.com/stem-cells-…
@Sernovabio @ALTuCELL @NextCellPharma @Mesoblast @Evotec @sanofi @OrgenesisInc @novonordisk @beta_o2 @EliLillyandCo @PharmaCyte @VertexPharma @aspectbiosys @newcelXltd
1
1
214
L2 Bio, LLC Launches C-ROW Site Beta: A Breakthrough Research Project in Costa Rica Targeting Osteoarthritis -
bioinformant.com/l2-bio-llc-…
95
May 27
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models - bioinformant.com/ernexa-ther…
@ErnexaTx
2
128
May 26
FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media - bioinformant.com/fujifilm-bi…
@FUJIFILMBiosci @NextCellPharma
84
May 18
Cartherics and Catalent Expand Commercial License Agreement - bioinformant.com/cartherics-…
@cartherics @Catalent_
142
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (#iPSC) -
bioinformant.com/pluristyx-q…
Congrats to the @pluristyx & @QkineBio teams on continuing to advance the iPSC field forward!
91
Apr 16
Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges - Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies
bioinformant.com/cell-easy-i…
139
Exciting news for MSC innovation: @RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China - bioinformant.com/roosterbio-…
122
Key Events in the Evolution of iPSC Products that You Need to Know - bioinformant.com/key-events-…
1
184
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases - bioinformant.com/catalent-an…
@Catalent_
144
Mar 30
Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform - bioinformant.com/gameto-lice…
@GametoGen @harvardmed @wyssinstitute
162
Mar 17
Longevity Medical Institute® Publishes Systematic Review of Stem Cell Safety Based on Landmark Human Clinical Trials - bioinformant.com/longevity-m… @Longevity_Cabo
2
152
Mar 17
Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing - bioinformant.com/green-eleph…
104
Mar 16
Congrats to the @_REPROCELL team on launching its new StemEdit Platform, a comprehensive gene editing platform for iPSCs & newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system.
Read more: bioinformant.com/reprocell-s…
#ipscells #geneediting #ai
215
Mar 13
Longevity Medical Institute® Physicians and Scientists Publish Peer-Reviewed Research on Stem Cell Therapies for Diabetic Foot Ulcers - bioinformant.com/longevity-m…
135
Mar 11
Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease - bioinformant.com/cytonome-su…
@cytonome
88
Mar 10
10 Biotherapies Books From @AABB To Add To Your Reading List In 2026 - bioinformant.com/10-biothera…
102
REPROCELL Introduces StemEdit Platform: AI-Designed Genome Editors & Hypoimmune iPSC Lines - bioinformant.com/reprocell-s…
@_REPROCELL
117
World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors - bioinformant.com/world-first…
3
7
482